The state of Rhode Island currently has 2 active clinical trials seeking participants for Ulcerative Colitis research studies. These trials are conducted in various cities, including Providence, Warwick, East Providence and Johnston.
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
NCT05230173
Recruiting
The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ulcerative colitis [UC]) in symptomatic remission with moderate to severe endoscopic inflammation despite optimization of index TIM in a real-world setting.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Gastroenterology Associates, Providence, Rhode Island
Conditions: Ulcerative Colitis, Crohn Disease
Register for Updates
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05767021
Recruiting
A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: University Gastroenterology, Providence, Rhode Island
Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic
Register for Updates